Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDUTNYSEARCA:KPRONYSEARCA:RATENASDAQ:XDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDUTGlobal X Education ETF$20.54$20.54$18.40▼$25.52$2.67M0.87477 shsN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETF$28.69-0.1%$28.20$25.76▼$28.72$2.87M0.32747 shs90 shsRATEGlobal X Interest Rate Hedge ETF$17.65-1.3%$18.71$17.12▼$21.62$2.47M2.191,740 shs101 shsXDNAKelly CRISPR & Gene Editing Technology ETF$7.38$7.38$5.87▼$11.83$2.21M0.923,034 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDUTGlobal X Education ETF0.00%0.00%0.00%0.00%0.00%KPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETF0.00%+1.48%+2.50%+2.17%+10.63%RATEGlobal X Interest Rate Hedge ETF0.00%-2.40%-3.92%-5.59%-11.58%XDNAKelly CRISPR & Gene Editing Technology ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDUTGlobal X Education ETFN/AN/AN/AN/AN/AN/AN/AN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/AN/AN/AN/AN/AN/AN/AN/ARATEGlobal X Interest Rate Hedge ETFN/AN/AN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDUTGlobal X Education ETF 2.29Hold$20.54N/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETF 0.00N/AN/AN/ARATEGlobal X Interest Rate Hedge ETF 0.00N/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDUTGlobal X Education ETFN/AN/AN/AN/AN/AN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/AN/AN/AN/AN/AN/ARATEGlobal X Interest Rate Hedge ETFN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDUTGlobal X Education ETFN/AN/A27.61∞N/AN/AN/AN/AN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/AN/A16.73∞N/AN/AN/AN/AN/ARATEGlobal X Interest Rate Hedge ETFN/A-$0.25N/A∞N/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/A17.02∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDUTGlobal X Education ETF$0.271.31%N/AN/AN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETF$0.993.45%N/AN/AN/ARATEGlobal X Interest Rate Hedge ETF$0.834.70%N/AN/A N/AXDNAKelly CRISPR & Gene Editing Technology ETFN/A0.12%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDUTGlobal X Education ETFN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/ARATEGlobal X Interest Rate Hedge ETF47.31%XDNAKelly CRISPR & Gene Editing Technology ETFN/AInsider OwnershipCompanyInsider OwnershipEDUTGlobal X Education ETFN/AKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/ARATEGlobal X Interest Rate Hedge ETF6.30%XDNAKelly CRISPR & Gene Editing Technology ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDUTGlobal X Education ETF147,000130,000N/ANot OptionableKPROKraneShares 100% KWEB Defined Outcome Through January 2026 ETFN/A100,000N/AN/ARATEGlobal X Interest Rate Hedge ETFN/A140,000N/ANot OptionableXDNAKelly CRISPR & Gene Editing Technology ETFN/A300,000N/AOptionableRATE, EDUT, XDNA, and KPRO HeadlinesRecent News About These CompaniesCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comBiotech investors: Stop expecting CRISPR science to make big leapsApril 14, 2025 | statnews.comSAI and gene editing promise ‘bespoke proteins’ for biotechOctober 8, 2024 | siliconrepublic.comSWeight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comVertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comCRISPR can treat common form of inherited blindness, early data hintMay 15, 2024 | msn.comCRISPR gene editing: in summaryMarch 27, 2024 | biotechniques.comBCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeMarch 8, 2024 | markets.businessinsider.comIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisFebruary 15, 2024 | markets.businessinsider.comCRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching ImplicationsJanuary 18, 2024 | techbullion.comTHere's Why CRISPR Therapeutics Stock Rose 54% Last YearJanuary 15, 2024 | msn.comGene editing is now a medical realityDecember 8, 2023 | news.yahoo.comFDA approves first use of CRISPR gene editing to treat sickle cell diseaseDecember 8, 2023 | news.yahoo.comFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderDecember 8, 2023 | markets.businessinsider.comGene Editing Will Change Medicine—and Maybe Health Investing TooNovember 24, 2023 | msn.comCRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breedingNovember 23, 2023 | phys.orgPIs CRISPR Therapeutics the Best Gene-Editing Stock?November 22, 2023 | msn.comThree people were gene-edited in an effort to cure their HIV. The result is unknown.November 16, 2023 | technologyreview.comTTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes InvestorsWhy SoundHound Could Be a Short Squeeze in the MakingBy Gabriel Osorio-Mazilli | June 2, 2025View Why SoundHound Could Be a Short Squeeze in the MakingRATE, EDUT, XDNA, and KPRO Company DescriptionsGlobal X Education ETF NASDAQ:EDUT$20.54 0.00 (0.00%) As of 06/27/2025The Global X Education ETF (EDUT) is an exchange-traded fund that is based on the Indxx Global Education Thematic index, a market-cap-weighted index of global companies providing products and services that facilitate education. EDUT was launched on Jul 10, 2020 and is managed by Global X.KraneShares 100% KWEB Defined Outcome Through January 2026 ETF NYSEARCA:KPRO$28.69 -0.03 (-0.10%) As of 04:10 PM EasternThe KraneShares 100% KWEB Defined Outcome January 2026 ETF (KPRO) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund seeks to track the total return of the KraneShares CSI China Internet ETF (KWEB) up to a cap, with a 100% downside hedge over a two-year outcome period. The actively managed fund holds shares of the underlying ETF and options to obtain exposure KPRO was launched on Feb 8, 2024 and is issued by KraneShares.Global X Interest Rate Hedge ETF NYSEARCA:RATE$17.65 -0.24 (-1.34%) As of 04:10 PM EasternThe Global X Interest Rate Hedge ETF (RATE) is an exchange-traded fund that mostly invests in spreads alternatives. The fund is an actively managed fund, using over-the-counter swaptions, which seeks to provide a hedge against sharp increases in long-term US interest rates. The fund is also expected to benefit during periods of market stress when interest rate volatility rises. RATE was launched on Jul 5, 2022 and is managed by Global X.Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA$7.38 0.00 (0.00%) As of 06/27/2025The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
